Briefly towards Biomarker-Driven Development and Their Global Impact in the Personalized and Precision Healthcare-Related Clinical Practice

¹Department for Clinical Allergology & Immunology of the Russian University of Medicine, Moscow, Russia

²The Russian Academy of Natural Sciences, Moscow, Russia

³EPMA, Brussels, EU

⁴PMC, Washington, USA

⁵AMEE, Dundee, Scotland

⁶AHA, Houston, TX, USA

⁷MGH, Boston, MA, USA

⁸Harvard Medical School, Boston, MA, USA

⁹ISPM, Tokyo, Japan

¹⁰Centre de Recherche Pharmaceutique de Paris (CRP2); Faculté de Pharmacie, Université Paris Descarte, Centre National de la Recherche Scientifique, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS) Inserm, Paris, France

¹¹Mayo Clinic, Rochester, MN, USA

¹²T College of Biological Sciences, UC Davis, CA, USA

¹³ResearchDx and PacificDx, Irvine, CA, USA

¹⁴Otakaro Pathways, Christchurch, New Zealand

¹⁵Medizinische Fakultät Mannheim der Universität Heidelberg II. Medizinische Klinik Molekulare Hepatologie, Germany

*Corresponding Author: Prof. Sergey Suchkov, Department for Clinical Allergology & Immunology of the Russian University of Medicine, Moscow, Russia, Tel: 89857616567, Email: [email protected].

Received Date: February 18, 2024

Published Date: March 15, 2024

Citation: Suchkov S, et al. (2024). Briefly towards Biomarker-Driven Development and Their Global Impact in the Personalized and Precision Healthcare-Related Clinical Practice. Mathews J Case Rep. 9(3):159.

Copyrights: Suchkov S, et al. © (2024).

ABSTRACT

Personalized and precision medicine relies on specific biomarkers to guide clinical decisions, distinguishing between predictive and prognostic biomarkers. Biomarkers are crucial in diagnosis, risk assessment, treatment guidance, and monitoring, with the potential to improve treatment outcomes. Biomarkers are clinically significant to a wide range of medical conditions, including cardiovascular diseases, autoimmune disorders, and neurodegenerative diseases. In cancer research, biomarkers enable risk assessment, diagnosis, prognosis determination, treatment prediction, therapy monitoring, and revolutionizing clinical decision-making. Designing trials for biomarker-guided therapy presents numerous challenges. Despite these, biomarker-guided trials are crucial for advancing personalized medicine and improving patient outcomes. New generation of biomarkers, particularly microRNAs are gathering attention into the realm of personalized and precision medicine due to their diagnostic, prognostic, and predictive biomarker potential. However, new types of biomarkers need to be researched and implemented to harness this potential. Additionally, this article discusses the integration of biomarkers into clinical practice, the direction of potential research, and the transformative impact new types of biomarkers can have on personalized medicine. Ultimately, the article emphasizes the significance of biomarker research in advancing personalized healthcare interventions, improving patient outcomes, and reshaping the healthcare landscape.

Keywords: Biomarker, Biomarker classification, Clinical trial, Companion diagnostics (CDx), Drug development, Personalized and Precision Medicine, Personalized treatment, Biodesign, Predictive biomarker, Prognostic biomarker.